Changes in management for patients with lung cancer referred for radical radiotherapy during the first wave of the COVID 19 pandemic in the UK (COVID-RT Lung)
Banfill, Kathryn Price, G Wicks, K Ahmad, S. Bainbridge, H. Bayne, M. Britten, A. Carson, C. Dorey, N. Goranov, B.
Banfill, Kathryn
Price, G
Wicks, K
Ahmad, S.
Bainbridge, H.
Bayne, M.
Britten, A.
Carson, C.
Dorey, N.
Goranov, B.
Citations
Altmetric:
Abstract
Introduction: In response to the COVID-19 pandemic, guidelines
on reduced fractionation for patients with lung cancer treated with
curative-intent radiotherapy (RT) were published, aiming to reduce
the number of hospital attendances and potential exposure of
vulnerable patients to SARS-CoV-2. Here we describe the changes
that have taken place.
Methods: COVID-RT Lung is a prospective, multicentre UK data
collection. Inclusion criteria are: patients with stage 1–3 lung cancer
referred for radical RT between 2/4/2020–2/10/2020. Both patients
who had a change in their management and those who continue
with standard management are included. Data on demographics,
COVID-19 diagnosis, diagnostic work-up, RT and systemic treatment,
treatment-related toxicity, disease/patient status are collected. Each
participating centre obtains local approval to collect data.
Anonymised data are collected on a central, cloud-based Research
Electronic Data Capture system.
Results: 1551 records from 30 UK RT sites were available for
analysis on 17/3/2021. 759 (49%) female, median age 72 years (37-
93 years). 641 patients (41%) had stage 3 disease. 489 patients
(31%) had a radiological diagnosis of lung cancer and 909 (59%) had
NSCLC. 21 patients (1.4%) were diagnosed with COVID-19, 6 during
radiotherapy. 193 patients (12%) had their diagnostic investigations
affected by the pandemic. 527 patients (34%) had their treatment
changed from their centre’s standard of care. 257 patients (16.6%)
had a change to their radiotherapy regimen; chemotherapy was
omitted in 82 patients (5.3%) and reduced in 70 (4.5%). Analysing
variations across the UK (Fig. 1), the North West of England had the highest proportion of patients who had their treatment changed
from their centre’s standard of care (48%).
Conclusion: This nationwide cohort shows that clinicians in the UK
changed the management of patients with stage 1–3 lung cancer in
line with national guidelines. Regions with high rates of COVID-19
changed management of a greater proportion of patients.
Authors
Banfill, Kathryn
Price, G
Wicks, K
Ahmad, S.
Bainbridge, H.
Bayne, M.
Britten, A.
Carson, C.
Dorey, N.
Goranov, B.
Guglani, S.
Harland, K.
Hatton, M.
Jayaprakash, K. T.
Hiley, C.
Jegannathen, A.
Koh, P.
Lord, H.
Mokhtar, D.
Panakis, N.
Peedell, C.
Pope, T.
Peters, A.
Powell, C.
Stilwell, C.
Treece, S.
Thomas, B.
Toy, E.
Zhou, S. Y
Faivre-Finn, Corinne
Price, G
Wicks, K
Ahmad, S.
Bainbridge, H.
Bayne, M.
Britten, A.
Carson, C.
Dorey, N.
Goranov, B.
Guglani, S.
Harland, K.
Hatton, M.
Jayaprakash, K. T.
Hiley, C.
Jegannathen, A.
Koh, P.
Lord, H.
Mokhtar, D.
Panakis, N.
Peedell, C.
Pope, T.
Peters, A.
Powell, C.
Stilwell, C.
Treece, S.
Thomas, B.
Toy, E.
Zhou, S. Y
Faivre-Finn, Corinne
Affiliation
Description
Date
2021
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Banfill KB, Price G, Wicks K, Ahmad S, Bainbridge H, Bayne M, et al. Changes in management for patients with lung cancer referred for radical radiotherapy during the first wave of the COVID 19 pandemic in the UK (COVID-RT Lung). Lung Cancer . 2021 Jun;156:S14.